Innate Pharma S.A.
IPHYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $54 | $66 | $70 | $71 |
| Short-Term Investments | $6 | $14 | $22 | $22 |
| Receivables | $0 | $2 | $0 | $46 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $3 | $19 | $9 |
| Total Curr. Assets | $65 | $86 | $112 | $148 |
| Property Plant & Equip (Net) | $5 | $5 | $6 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $10 | $10 | $10 | $10 |
| Tax Assets | $0 | $0 | $9 | $9 |
| Other NC Assets | $13 | $10 | $15 | $2 |
| Total NC Assets | $28 | $25 | $40 | $27 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $93 | $111 | $151 | $175 |
| Liabilities | – | – | – | – |
| Payables | $5 | $8 | $9 | $9 |
| Short-Term Debt | $9 | $9 | $9 | $9 |
| Tax Payable | $0 | $7 | $6 | $7 |
| Deferred Revenue | $0 | $1 | $0 | $6 |
| Other Curr. Liab. | $16 | $9 | $15 | $9 |
| Total Curr. Liab. | $29 | $33 | $38 | $40 |
| LT Debt | $18 | $22 | $27 | $31 |
| Deferred Rev, NC | $0 | $3 | $0 | $5 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $9 |
| Other NC Liab. | $40 | $44 | $58 | $39 |
| Total NC Liab. | $58 | $69 | $84 | $84 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $0 | $1 | $1 |
| Total Liabilities | $88 | $102 | $123 | $123 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $5 | $4 | $4 | $4 |
| Retained Earnings | -$408 | -$386 | -$362 | -$337 |
| AOCI | $1 | $0 | $0 | $0 |
| Other Equity | $407 | $391 | $386 | $384 |
| Total Equity | $5 | $9 | $29 | $52 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $93 | $111 | $151 | $175 |
| Net Debt | -$27 | -$35 | -$34 | -$31 |